Observational study in patients with HR+ / HER2- metastatic breast cancer treated with Abemaciclib. Review of medical records
COMMERCIAL POST AUTHORIZATION STUDY
Clinical trial information
- Promoter: LILLY, SAU
- Execution start: 19/03/2021
- End of execution: 01/04/2022
- IP: ISABEL BLANCAS LOPEZ-BARAJAS